Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 15/20 | 0.49 |
| ▸ | IKBKB | O14920 | 4/20 | 0.36 |
| ▸ | CHUK | O15111 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1496121 | 0.92 | CHEK1 (0.45) | CHEK1JAK2KCNH2LRRK2 | |
| SCHEMBL1496116 | 0.91 | CHEK1 (0.49) | CHEK1KCNH2LRRK2 | |
| SCHEMBL1495988 | 0.91 | CHEK1 (0.60) | CHEK1IKBKB | |
| SCHEMBL1496149 | 0.86 | CHEK1 (0.45) | CHEK1KCNH2 | |
| SCHEMBL1496161 | 0.86 | CHEK1 (0.51) | CHEK1IKBKBJAK2KCNH2 | |
| SCHEMBL1496133 | 0.77 | CHEK1 (0.57) | CHEK1KCNH2LRRK2 | |
| SCHEMBL1496013 | 0.76 | CHEK1 (0.58) | CHEK1KCNH2 | |
| SCHEMBL1496019 | 0.76 | CHEK1 (0.60) | CHEK1KCNH2 | |
| SCHEMBL1496140 | 0.76 | CHEK1 (0.75) | CHEK1KCNH2 | |
| SCHEMBL1496087 | 0.76 | CHEK1 (0.43) | CHEK1IKBKBCHUKCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240009190-A1 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | Shanghai Huayu Biotechnology Co., Ltd. (CN) | 2024-01-11 | — | — | US | claimed |
| US-20230049029-A1 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | Shanghai Huayu Biotechnology Co., Ltd. (CN) | 2023-02-16 | — | — | US | claimed |
| WO-2021141980-A1 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | WU FAN (US) | 2021-07-15 | — | — | WO | claimed |
| WO-2021141974-A2 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | WU FAN (US) | 2021-07-15 | — | — | WO | claimed |
| US-20150072987-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | SHANGHAI HUAYU BIOTECH CO., LTD (CN) | 2015-03-12 | — | — | US | claimed |
| US-8815863-B2 | Compounds and therapeutic use thereof for protein kinase inhibition | SHANGHAI HUAYU BIOTECH CO., LTD. (CN) | 2014-08-26 | — | — | US | claimed |
| US-20120232082-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | SHANGHAI HUAYU BIOTECH CO., LTD. (CN) | 2012-09-13 | — | — | US | claimed |
| US-20240009190-A1 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | Shanghai Huayu Biotechnology Co., Ltd. (CN) | 2024-01-11 | — | — | US | disclosed |
| US-20230049029-A1 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | Shanghai Huayu Biotechnology Co., Ltd. (CN) | 2023-02-16 | — | — | US | disclosed |
| WO-2021141980-A1 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | WU FAN (US) | 2021-07-15 | — | — | WO | disclosed |
| WO-2021141974-A2 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | WU FAN (US) | 2021-07-15 | — | — | WO | disclosed |
| US-9487539-B2 | Compounds and therapeutic use thereof for protein kinase inhibition | SHANGHAI HUAYU BIOTECH CO., LTD (CN) | 2016-11-08 | — | — | US | disclosed |
| EP-2826780-B1 | Thieno[2,3-d]pyridazine derivatives and therapeutic use thereof for protein kinase inhibition | WU ZHANGGUI (US) | 2016-06-01 | — | — | EP | disclosed |
| US-20150072987-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | SHANGHAI HUAYU BIOTECH CO., LTD (CN) | 2015-03-12 | — | — | US | disclosed |
| EP-2826780-A1 | Thieno[2,3-d]pyridazine derivatives and therapeutic use thereof for protein kinase inhibition | Wu, Zhanggui (US) | 2015-01-21 | — | — | EP | disclosed |
| US-8815863-B2 | Compounds and therapeutic use thereof for protein kinase inhibition | SHANGHAI HUAYU BIOTECH CO., LTD. (CN) | 2014-08-26 | — | — | US | disclosed |
| EP-2477496-B1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | WU ZHANGGUI (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20120232082-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | SHANGHAI HUAYU BIOTECH CO., LTD. (CN) | 2012-09-13 | — | — | US | disclosed |
| EP-2477496-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | Wu, Zhanggui (US) | 2012-07-25 | — | — | EP | disclosed |
| WO-2011035077-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | WU ZHANGGUI (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230049029-A1 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | CHEK1, DCK, CHEK2 | CHEK1 1/4885IKBKB 532/4885CHUK 217/4885 |
| US-20240009190-A1 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | CHEK1, CHEK2, DCK | CHEK1 1/4885IKBKB 377/4885CHUK 193/4885 |
| US-20150072987-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | CHEK2, CHEK1, PLK1 | CHEK1 2/4885IKBKB 576/4885CHUK 226/4885 |
| US-20120232082-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | CHEK2, CHEK1, BUB1B | CHEK1 2/4885IKBKB 575/4885CHUK 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.